Blog

However, when the product was administered to mice bearing small tumors (i.e., 3 or 6 days after subcutaneous injection of B16 cells), only a minimal tumor growth retardation was observed [Physique 4A]. scFv format fused to murine TNF. This fusion protein efficiently killed endothelial cellsin vitro, while displaying only minimal activity against B16 melanoma cells.In Edonerpic maleate vivo, TA99-mTNF boosted the influx of NK cells into B16 melanoma lesions. Therapy studies with two different administration schedules revealed that this combination of TA99-mTNF and IgG2a(TA99) was superior to the individual products used as single agents. The combination treatment converted most of the tumor mass into a necrotic lesion, but a vital tumor rim eventually regrew. The treatment modality explained in this article may be relevant for the treatment of melanoma patients, given the specificity of the gp75 antigen and its conservation across species. Addition of a third combination partner may be required, in order to eradicate the last tumor cells, which survive treatment. Keywords:Antibody-dependent cell-mediated cytotoxicity, malignancy immunotherapy, immunocytokines, Tumor necrosis factor, melanoma == Introduction == Intact antibodies in IgG format can be efficacious for the selective depletion of certain lymphocyte populations and for the treatment of hematological malignancies [13]. However, antibody-dependent cell-mediated cytotoxicity (ADCC) is much less efficient against solid tumors [4,5]. An efficient implementation of ADCC would be highly desired for pharmaceutical applications. In principle, if the target antigen was specifically expressed on tumor cells, IgGs capable of connecting tumor cells with the killing power of NK cells would come close to an embodiment of those magic bullets (Zauberkugeln), originally envisaged by Paul Ehrlich [6]. The cell membrane gp75 antigen is usually selectively expressed in melanocytes and in melanoma cells, but is usually normally undetectable in all other normal tissues [7,8]. This antigen, which is usually conserved from mouse to man [9], represents an ideal target for antibody-based pharmaceutical applications and an excellent model system to study ADCC. The group of Jeffrey Ravetch experienced clearly demonstrated that this simultaneous intravenous administration of B16 melanoma cells and of the gp75-specific TA99 antibody in murine IgG2a format could efficiently prevent formation of lung metastases in immunocompetent mice [10]. The antibody isotype was important, as murine IgG variants with lower affinity towards cognate FcRIV and FcRI did not display a similar anti-cancer activity [1012]. Other reports, performed using IgG2a(TA99), experienced shown that this agent could not eradicate melanoma lesions, once the Rabbit Polyclonal to SH3GLB2 tumors experienced established as small subcutaneous solid nodules [1315]. With our work, we aimed at characterizing the tumor-homing properties and therapeutic activity of murine IgG2a(TA99), alone or in combination with other modalities. Cytokine-based therapeutics can substantially boost ADCC activity in mouse models of malignancy. There is a considerable Edonerpic maleate biomedical desire for the use of designed cytokines [1620].The recent transaction for any PEGylated version of interleukin-2 (NKTR-214) has been dubbed the largest licensing deal in the pharmaceutical industry [21]. Wittrup and colleagues have recently reported that this ADCC activity of the intact immunoglobulin TA99 could be substantially enhanced by combination with an Fc fusion Edonerpic maleate of murine interleukin-2 [15]. Similarly, we have previously described that this ADCC activity of IgG therapeutics can be boosted by the antibody-based delivery of interleukin-2 in mouse models of malignancy [22,23] and in patients [24,25]. In addition to interleukin-2, also the antibody-based delivery of tumor necrosis factor (TNF) to the tumor environment holds promises for the implementation of an efficient anti-cancer therapy. TNF may display a direct anti-cancer activity against certain malignancy cell types and against endothelial cells [26,27]. This strong pro-inflammatory cytokine may also favor the uptake of therapeutics into the solid tumor mass [28,29]. We have recently shown that this antibody-based delivery of murine TNF to splice variants of fibronectin prospects to the complete eradication of soft-tissue sarcoma in immunocompetent mouse models [3032]. Interestingly, cured mice were able to reject subsequent difficulties of heterologous tumor cells from your same mouse strain, in a mechanism that depended on CD8+T cells, realizing an endogenous retroviral antigen [32]. Motivated by these results and by the tolerability of TNF fusions in patients [33,34], the L19-TNF fusion protein has recently progressed to Phase III clinical trials, for the treatment of patients with metastatic soft-tissue sarcoma [NCT02076620]. Antibody-TNF fusions capable of selective localization at the tumor site promote hemorrhagic necrosis of neoplastic lesions and favor the influx of leukocytes (including NK cells and macrophage) into the tumor mass [27,29,35]. Collectively, Edonerpic maleate these findings suggest that the targeted delivery of TNF may be considered as a strategy for ADCC potentiation. In this Edonerpic maleate article, we have characterized the tumor homing properties and anti-cancer activity of murine IgG2a(TA99) in B16 melanoma, both as single agent and in.